Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 27, 2025Journal of Biopharmaceutical Statistics

M-DODII: Bayesian dose optimization design for randomized phase II study with multiple indications

View Full Paper
Ask AI
Bookmark
Share

Authors

ZYZiji YuTakeda (United States)RLRachael LiuTakeda (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yu et al. (2025) studied this question.

synapsesocial.com/papers/694031bd2d562116f29067d5https://doi.org/10.1080/10543406.2025.2589731
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A predictive probability design for phase II cancer clinical trials2008 · 183 citations
  2. 2Bayesian Semi-parametric Design (BSD) for adaptive dose-finding with multiple strata2020 · 27 citations
  3. 3Adaptive Two‐Stage Designs for Single‐Arm Phase IIA Cancer Clinical Trials2004 · 93 citations
  4. 4A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints2022 · 8 citations
  5. 5A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation2014 · 34 citations